If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMED.L Regulatory News (MED)

  • There is currently no data for MED

Trading Update

8 Jan 2020 07:00

RNS Number : 0725Z
Intelligent Ultrasound Group PLC
08 January 2020
 

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Company" or the "Group")

 

Trading Update

 

Intelligent Ultrasound Group plc (AIM: MED), the ultrasound artificial intelligence (AI) software and simulation company, announces that Group revenue for the year to 31 December 2019, which is currently generated entirely by the Group's Simulation Division, is expected to grow by around 10% from the £5.3m achieved in 2018 to between £5.7m and £5.9m. The Group is pleased that the Division continued to show year on year growth and the important agreement signed with FUJIFILM SonoSite Inc. in the second half of the year, will help increase future sales in the Division's point-of-care ultrasound (POCUS) training market.

 

The Group's pre-revenue Clinical Artificial Intelligence Division had a very successful year, meeting all its commercial and development milestones. By signing its first long-term licence and co-development agreement in July 2019 with one of the world's leading ultrasound equipment manufacturers for its AI-based real-time ultrasound imaging software, the Group made a significant advance in validating its commercial model. Following the completion of the pre-regulatory development of AnatomyGuide, the Division's latest AI-based real-time software product, commercial discussions are now being progressed to bring AnatomyGuide to market. To support future developments, the Division's AI image database has been expanded so it now exceeds over four million ultrasound images.

 

The EBITDA loss for the year is expected to be between £3.3m and £3.4m (2018: loss, £2.7m). This includes approximately £2.0m (2018: £1.3m) of primarily R&D costs attributable to investment in the Group's Clinical Artificial Intelligence Division. Group management, PLC costs and share-based payment charges included in the loss are expected to be £1.0m (2018: £0.9m).

 

£5.9m net of costs was received in August 2019 from the successful placing and open offer. Cash in bank at 31 December 2019 was £7.3m (2018: £5.6m).

 

Stuart Gall, Group CEO, commented: "This has been a strong year for the Group. The Clinical Artificial Intelligence Division has performed particularly well, signing its first licensing agreement with a major OEM and progressing commercial discussions for its second AI software product. The reception the Company received at the annual Radiological Society of North America meeting (RSNA) in Chicago was also particularly encouraging. The Simulation Division has worked hard to continue growing revenue and we are confident of continuing the Group's revenue growth in 2020."

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Intelligent Ultrasound Group plc 

www.intelligentultrasound.com

Stuart Gall, CEO Helen Jones, Group Finance Director

Tel: +44 (0)29 2075 6534 

 

 

Cenkos Securities - Nominated Advisor and broker

Tel: +44 (0)20 7397 8900 

Giles Balleny / Cameron MacRitchie (Corporate Finance)

 

Michael Johnson / Julian Morse (Sales) 

 

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893

    

 

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.

Based in Cardiff and Oxford in the UK, Atlanta in the US and with representation in Beijing in Asia, the Group operates two divisions:

Clinical AI Division

Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.

 

Simulation Division

Focusses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 800 simulators have been sold to almost 500 medical institutions around the world.

 

www.intelligentultrasound.com 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFIFSILLITIII
Date   Source Headline
14th Jan 201911:34 amRNSChange of Name
7th Jan 20197:00 amRNSTrading Update
14th Dec 20181:05 pmRNSHolding(s) in Company
13th Dec 20188:30 amRNSDirector/PDMR Shareholding
12th Dec 20181:24 pmRNSResults of General Meeting and Total Voting Rights
12th Dec 20187:00 amRNSResults of Open Offer
27th Nov 20183:35 pmRNSAI database exceeds 1 million images
26th Nov 20187:00 amRNSPlacing to raise £5.0m
23rd Nov 20183:56 pmRNSMedaPhor commences clinical trial for AnatomyGuide
13th Nov 20187:00 amRNSQuality control on ultrasound for HAPIN trial
9th Nov 20187:00 amRNSINTERGROWTH-21st Project the University of Oxford
10th Oct 20182:59 pmRNSHolding(s) in Company
9th Oct 20188:01 amRNSDirector/PDMR Shareholding
8th Oct 20187:00 amRNSPayment of deferred consideration
25th Jul 20187:00 amRNSHalf-year Report
23rd Jul 20187:00 amRNSMedaphor expands ScanNav AI pilot
7th Jun 20187:00 amRNSScanTrainer at Central Middlesex Hospital
30th May 20187:00 amRNSGrant of Options
29th May 20187:00 amRNSBodyWorks Eve installed at NYU School of Medicine
17th May 201810:54 amRNSResult of AGM
17th May 20187:00 amRNSAGM Statement
14th May 20187:00 amRNSScanNav AI software featured on ITV
24th Apr 20187:00 amRNSNotice of AGM
21st Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of Results
21st Feb 20187:00 amRNSOpening of Hong Kong office
19th Feb 20187:00 amRNSLaunch of new Point-of-Care Ultrasound simulator
12th Feb 20187:00 amRNSPilot of ultrasound AI software for pregnancy scan
7th Feb 20187:00 amRNSInvestor presentation
5th Feb 20187:00 amRNSInnovate UK grant award confirmed
3rd Jan 20187:00 amRNSTrading and IUL integration update
23rd Nov 20177:00 amRNSInnovate UK Grant Award
30th Oct 20173:19 pmRNSDirector Appointment
18th Oct 201712:46 pmRNSHolding(s) in Company
17th Oct 201711:05 amRNSSecond Price Monitoring Extn
17th Oct 201711:00 amRNSPrice Monitoring Extension
11th Oct 20178:17 amRNSHolding(s) in Company
10th Oct 20171:55 pmRNSHolding(s) in Company
9th Oct 20173:23 pmRNSHolding(s) in Company
9th Oct 20172:51 pmRNSHolding(s) in Company
6th Oct 20178:00 amRNSCompletion of Acquisition
5th Oct 201711:18 amRNSResult of General Meeting
21st Sep 20171:31 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSContract awarded at Mohawk College in Canada
19th Sep 20173:40 pmRNSAcquisition & Placing
17th Aug 20177:00 amRNSInstallation of 500th simulation system
10th Aug 20178:37 amRNSPayment of deferred consideration
31st Jul 20177:00 amRNSHalf-year Report
24th Jul 20177:00 amRNSMedaPhor wins first ScanTrainer customer in India
23rd May 201711:44 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.